Searched for
LUPIN PHARMACEUTICALS
Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin arm recalls 5,720 skin treatment cream tubes in USThe affected lot has been manufactured at the company's Pithampur plant in Madhya Pradesh and marketed in the US market by Baltimore-based ...
- Lupin recalls over 16k bottles of generic tuberculosis drug in USAs per the latest Enforcement Report by the US health regulator, Lupin Pharmaceuticals Inc, a US-based arm of the Mumbai-based drug major, ...
- Lupin, Sun Pharma, Jubilant Cadista recall drugs in US marketAccording to the USFDA, the company is recalling the affected lot for being "Superpotent". The affected lot has been manufactured at Lupin'...
- Lupin gets USFDA approval for diarrhoea drugLupin Pharmaceuticals Inc (LPI), the company's US subsidiary would commence marketing the product shortly.
- Lupin eyes growth via strategic brand acquisitions in United StatesLupin Ltd is looking at strengthening branded portfolio with the launch of additional products developed and filed with the USFDA from its ...
- Lupin Pharmaceuticals gets final USFDA nod for generic antibioticsThe approval by the USFDA has been granted to the company's subsidiary, Lupin Pharmaceuticals Inc for tablets of 65 mg, 80 mg, 105 mg and 1...
- Lupin gets tentative USFDA approval for Pregabalin; stk upLupin’s subsidiary Lupin Pharmaceuticals Inc has received tentative ANDA approval for its Pregabalin capsules from the USFDA.
- Lupin settles litigation over Lunesta tablets; stock upPharma major Lupin and its subsidiary Lupin Pharmaceuticals Inc have settled ongoing litigation with Sunovion Pharmaceuticals over Lunesta ...
- GeNext to prescribe new growth formula for LupinDesh Bandhu Gupta built Lupin into a $1-billion enterprise, but he will chart the journey to $3 billion and beyond with his two children.
Load More
